A phase II study of gemcitabine in the treatment of non small cell lung cancer;Etude multicentrique de phase II de la gemcitabine dans les cancers bronchiques non a petites cellules (CBNPC)

Bulletin du Cancer

Volumn 84, Issue 3, 1997, Pages 282-288

  Le Chevalier, Thierry ^a   Gottfried, Maya ^a   Gatzemeier, Ulrich ^b   Shepherd, Frances ^c   Weynants, P ^d   Cottier, B ^e   Groen, H J M ^f   Rosso, Ricardo ^g   Mattson, Karin ^h   Cortes Funes, Herman ⁱ   Tonato, Maurizio ^j   Burkes, Ronald L ^k   Voi, Maurizio ^l   Ponzio, Anne ^m  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b Krankenhaus Grosshandorf   (France)

^c TORONTO GENERAL HOSPITAL   (Canada)

^d UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^e CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g UNIVERSITY OF GENOA   (Italy)

^h HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

ⁱ HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^j Ospedale   (Italy)

^k Pediatric Oral and Maxillofacial Surgery   (Canada)

^l ELI LILLY AND COMPANY   (United States)

^m Lilly France   (France)

more..

Author keywords

gemcitabine; monotherapy; non small cell lung cancer (NSCLC); phase II

Indexed keywords

GEMCITABINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; EDEMA; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; VOMITING;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 8244241093     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Abbruzzese JL, Grunewald R, Weeks EA, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991 ; 9: 491-8.
2. Abratt R, Bezwoda W, Falkson G, et al. Efficacy and safety profile of gemcitabine in non-small cell lung cancer: a phase II study. J Clin Oncol 1994; 12: 1535-40.
3. Anderson H, Lund B, Boch F, et al. Single agent activity of weekly gemcitabine in advanced non-small cell lung cancer: a phase II study. J Clin Oncol 1994 ; 12 : 1821-6.
4. Boring CC, Squires TS, Tang T. Cancer statistics. CA 1991 ; 41 : 19-36.
5. Braakhuis BJM, Van Dongen GAMS, Vermorken JB, et al. Preclinical in vivo activity of 2′,2′-difluorodeoxycytidine (gemcitabine) against human head and neck cancer. Cancer Res 1991 ; 51 : 211-4.
6. Carmichael J, Possinger K, Philip P, et al. Difluorodeoxycytidine (gemcitabine): a phase II study in patients with advanced breast cancer. Proc Am Soc Clin Oncol 1993 ; 12 : 64.
7. Chang AY, Kim K, Glick J, et al. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small cell lung cancer: the Eastern Cooperative Oncology Group Results. J Natl Cancer Inst 1993 ; 85 : 388-94.
8. Depierre A, Lemarie E, Dabouis G, et al. A phase II study of navelbine (vinorelbine) in the treatment of non-small cell lung cancer. Am J Clin Oncol (CCT) 1991 ; 14: 115-9.
9. Fujita M, Fujita F, Inaba H, et al. Investigations of anti-tumor effects of LY 188011 (gemcitabine) against human cancer xenografts in nude mice. Jpn J Cancer Chemother 1994 ; 21 : 517-23.
10. Fukuoka M, Niitani H, Suzuki A, et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small cell lung cancer. J Clin Oncol 1992 ; 10 : 16-20.
11. Heinemann V, Hertel LW, Grindey GB, et al. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res 1988; 48: 4024-31.
12. Hertel LW, Boder GB, Kroin JS, et al. Evaluation of the antitumor activity of gemcitabine, (difluoro-2β-deoxycytidine). Cancer Res 1990 ; 50 : 4417-22.
13. Huang P, Chubb S, Hertel L, et al. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991 ; 51 : 6110-7.
14. Ihde DC, Minna JD. Non-small cell lung cancer. I. Biology, diagnosis and staging. Curr Probl Cancer 1991 ; 15 : 61-104.
15. Ihde DC. Chemotherapy of lung cancer. N Engl J Med 1992; 327: 1434-41.
16. Le Chevalier T, Brisgand D, Pujol JL, et al. Résultats d'une étude randomisée comparant l'association navelbine-cisplatinum à l'association vindésine-cisplatinum et à la navelbine seule chez 612 malades porteurs d'un carcinome bronchique non à petites cellules inopérable. Bull Cancer 1996 ; 83 : 385-94.
17. Le Chevalier T. Chimiothérapie des cancers bronchiques non à petites cellules. Presse Med 1996 ; 25 : 1699-703.
18. Lenzi R, Fossella FV, Lee JS. Systemic treatment of non-small cell lung cancer. Compre Ther 1992; 18: 27-30.
19. Lund B, Hansen OP, Theilade K, et al. Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine| in previously treated ovarian cancer. J Natl Cancer Inst 1997 (sous presse).
20. Martoni A, Guaraldi M, Casadio M, et al. A phase II study of high-dose epirubicin plus cisplatinum in advanced non-small cell lung cancer (NSCLC). Ann Oncol 1992 ; 3 : 864-6.
21. Murphy WK, Fosella FV, Winn RJ, et al. Phase II study of taxol in patients with untreated advanced non-small cell lung cancer. J Natl Cancer Inst 1993 ; 85 : 384-8.
22. Plunkett W, Gandhi V, Chubbs S, et al. 2′,2′-difluorodeoxycytidine metabolism and mechanism of action in human leukaemia cells. Nucleosides Nucleotides 1989 ; 8 : 775-85.
23. Ries LAG, Hankey BF, Miller BA, et al. Cancer Statistics Review 1973-1988. NIH publication no. 91.2789, Bethesda, MD, National Cancer Institute, 1991.
24. Sandler AB, Buzaid AC. Lung cancer: a review of current therapeutic modalities. Lung 1992 ; 170 : 249-65.
25. Schultz RM, Merriman RL, Toth JE, et al. Evaluation of new anticancer agents against the MIA PaCa-2 and PANC-1 human pancreatic carcinoma xenografts. Oncology Res 1993 ; 5 : 223-8.
26. Shum KY, Kris MG, Gralla RJ, et al. Phase II study of 10-ethyl-10-deaza-aminopterin in patients with stage III and IV non-small cell lung cancer. J Clin Oncol 1988 ; 6 : 446-50.
27. Smit EF, Piers DA, Postmus PE. Phase II study of high-dose epirubicin and etoposide in advanced non-small cell lung cancer. Eur J Cancer Part 1992 ; 28 : 1965-7.
28. Smith IE. Palliative chemotherapy for advanced non-small cell lung cancer. Brit Med J 1994; 308: 429-30.
29. Souham RL, Rudd RM, Spiro SG, et al. Phase II study of edatrexate in stage III and IV non-small cell lung cancer. Cancer Chemother Pharmacol 1992 ; 30 : 465-8.
30. Splinter TAW. Chemotherapy in advanced non-small cell lung cancer. Eur J Cancer 1990 ; 26 : 1093-9.
31. Wils J, Utama I, Sala L, et al. Phase II study of high-dose epirubicin in non-small cell lung cancer. Eur J Cancer 1990 ; 26 : 1140-1.
32. Xu Y-Z, Plunkett W. Modulation of deoxycytidylate deaminase in intact human leukemia cells. Action of 2′,2′-difluorodeoxycytidine. Biochem Pharmacol 1992 ; 44 : 1819-27.